These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 8265978)

  • 1. Variability of tumor markers in the follow-up of patients radically resected for breast cancer.
    Gion M; Cappelli G; Mione R; Vignati G; Fortunato A; Saracchini S; Biasioli R; Gulisano M
    Tumour Biol; 1993; 14(6):325-33. PubMed ID: 8265978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of critical differences of CEA and CA 15.3 levels in serial samples from patients operated for breast cancer.
    Gion M; Cappelli G; Mione R; Pistorello M; Meo S; Vignati G; Fortunato A; Saracchini S; Biasioli R; Giulisano M
    Int J Biol Markers; 1994; 9(3):135-9. PubMed ID: 7829892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of preoperative CA 15-3 levels in operable breast cancer. Comparison with tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA).
    Iaffaioli RV; Caponigro F; Esposito G; Pagliarulo C; Deplacido S; Ungaro B; Bazzicalupo L; Frasci G; Bianco AR
    Int J Biol Markers; 1991; 6(1):21-4. PubMed ID: 1856513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breast cancer and clinical utility of CA 15-3 and CEA.
    Jäger W; Krämer S; Palapelas V; Norbert L
    Scand J Clin Lab Invest Suppl; 1995; 221():87-92. PubMed ID: 7652494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new approach to tumour marker assessment by perioperative determination in breast and colorectal cancer.
    Gion M; Ruggeri G; Mione R; Marconato R; Casella C; Nosadini A; Simoncini E; Belloli S; Dal Zennaro E; Bruscagnin G
    Int J Biol Markers; 1993; 8(1):8-13. PubMed ID: 8496629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interpretation of results for tumor markers on the basis of analytical imprecision and biological variation.
    Sölétormos G; Schiøler V; Nielsen D; Skovsgaard T; Dombernowsky P
    Clin Chem; 1993 Oct; 39(10):2077-83. PubMed ID: 8403393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Is follow-up of breast cancer with CEA and CA 15-3 justified?].
    Fritsche E; Benz J
    Helv Chir Acta; 1992 May; 59(1):225-9. PubMed ID: 1526832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CEA and CA 15-3 in primary and recurrent breast cancer.
    O'Dwyer PJ; Duffy MJ; O'Sullivan F; McDermott E; Losty P; O'Higgins NJ
    World J Surg; 1990; 14(5):562-5; discussion 565-6. PubMed ID: 2238654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of CA 15.3, CEA and TPA concentrations during monitoring of breast cancer.
    Sölétormos G; Petersen PH; Dombernowsky P
    Clin Chem Lab Med; 2000 May; 38(5):453-63. PubMed ID: 10952230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating CA 549 and other associated antigens in breast cancer patients.
    Pavesi F; Lotzniker M; Scarabelli M; Mauro E; Visconti G; Nicolato E; Moratti R
    Oncology; 1994; 51(1):18-21. PubMed ID: 8265097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Individual reference ranges of CA 15-3, MCA and CEA in recurrence of breast cancer.
    Hölzel WG; Beer R; Deschner W; Griesmacher A; Müller MM
    Scand J Clin Lab Invest Suppl; 1995; 221():93-101. PubMed ID: 7652495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum CA-15.3 and CEA patterns in postsurgical follow-up, and in monitoring clinical course of metastatic cancer in patients with breast carcinoma.
    al-Jarallah MA; Behbehani AE; el-Nass SA; Temim L; Ebraheem AK; Ali MA; Szymendera JJ
    Eur J Surg Oncol; 1993 Feb; 19(1):74-9. PubMed ID: 8436243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Tumor markers CEA, CA 15-3, MCA, TPA, ferritin and PTH in the diagnosis and monitoring of primary breast cancer].
    Letiagin VP; Vysotskaia IV
    Vestn Ross Akad Med Nauk; 1995; (4):10-4. PubMed ID: 7780332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
    Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
    Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.
    Nicolini A; Tartarelli G; Carpi A; Metelli MR; Ferrari P; Anselmi L; Conte M; Berti P; Miccoli P
    BMC Cancer; 2006 Nov; 6():269. PubMed ID: 17116247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the circulating glycoprotein CA549 in mammary cancer and other malignancies.
    Clocchiatti L; De Biasi F; Cartei G; Sibau A; Vigevani E; Signor M; Giovannoni M; Ceschia V; Di Chiara F; Grandis S
    Tumori; 1991 Oct; 77(5):395-8. PubMed ID: 1781036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum CEA, CA 15-3, and MCA in breast cancer patients: a clinical evaluation.
    Repetto L; Onetto M; Gardin G; Costanzi B; Giudici S; Vitiello E; Merlini L; Naso C; Zannini C; Paganuzzi M
    Cancer Detect Prev; 1993; 17(3):411-5. PubMed ID: 8402728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined detection of CEA, CA 19-9, CA 242 and CA 50 in the diagnosis and prognosis of resectable gastric cancer.
    Tian SB; Yu JC; Kang WM; Ma ZQ; Ye X; Cao ZJ; Yan C
    Asian Pac J Cancer Prev; 2014; 15(15):6295-300. PubMed ID: 25124614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum and immunohistochemical studies of NCC-ST-439 in breast cancer.
    Narita T; Funahashi H; Satoh Y; Imai T; Takagi H
    J Surg Oncol; 1993 Sep; 54(1):5-8. PubMed ID: 8377506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The diagnostic value of CA 27-29, CA 15-3, mucin-like carcinoma antigen, carcinoembryonic antigen and CA 19-9 in breast and gastrointestinal malignancies.
    Frenette PS; Thirlwell MP; Trudeau M; Thomson DM; Joseph L; Shuster JS
    Tumour Biol; 1994; 15(5):247-54. PubMed ID: 7991985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.